Emilia Scalzulli1, Ida Carmosino1, Maria Laura Bisegna1, Maurizio Martelli1, Massimo Breccia2. 1. Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Via Benevento 6, 00161, Rome, Italy. 2. Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it.
Abstract
PURPOSE OF REVIEW: The clinical scenario for chronic myeloid leukemia patients rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs). Second-generation TKIs as frontline treatment increased the rate of deep molecular responses without increasing the rate of overall survival. About 20% of patients experience resistance to these agents, needing alternative treatments. Here, we reviewed the possible mechanisms of resistance, available treatment, and new drugs developed to counteract and overcome resistance. RECENT FINDINGS: Results of novel TKIs have been recently reported, especially for the setting of T315I mutated patients, such as olverembatinib and asciminib, or for patients who developed resistance due to other mutations, such as vodobatinib. Most of new TKIs are selected among compounds tested selective on ABL, therefore without possible off-target effects in the long term. New potential treatments are on the horizon in the field of CML, able to rescue patients treated firstly with one or more second-generation TKIs. Results of ongoing trials and real-world evidence dataset will help us to identify the appropriate timing of intervention and to select appropriate candidate to these drugs.
PURPOSE OF REVIEW: The clinical scenario for chronic myeloid leukemia patients rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs). Second-generation TKIs as frontline treatment increased the rate of deep molecular responses without increasing the rate of overall survival. About 20% of patients experience resistance to these agents, needing alternative treatments. Here, we reviewed the possible mechanisms of resistance, available treatment, and new drugs developed to counteract and overcome resistance. RECENT FINDINGS: Results of novel TKIs have been recently reported, especially for the setting of T315I mutated patients, such as olverembatinib and asciminib, or for patients who developed resistance due to other mutations, such as vodobatinib. Most of new TKIs are selected among compounds tested selective on ABL, therefore without possible off-target effects in the long term. New potential treatments are on the horizon in the field of CML, able to rescue patients treated firstly with one or more second-generation TKIs. Results of ongoing trials and real-world evidence dataset will help us to identify the appropriate timing of intervention and to select appropriate candidate to these drugs.
Authors: V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann Journal: Leukemia Date: 2015-03-18 Impact factor: 11.528
Authors: Simona Soverini; Susan Branford; Franck E Nicolini; Moshe Talpaz; Michael W N Deininger; Giovanni Martinelli; Martin C Müller; Jerald P Radich; Neil P Shah Journal: Leuk Res Date: 2013-09-23 Impact factor: 3.156
Authors: Jorge E Cortes; Giuseppe Saglio; Hagop M Kantarjian; Michele Baccarani; Jiří Mayer; Concepción Boqué; Neil P Shah; Charles Chuah; Luis Casanova; Brigid Bradley-Garelik; George Manos; Andreas Hochhaus Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: A Hochhaus; G Rosti; N C P Cross; J L Steegmann; P le Coutre; G Ossenkoppele; L Petrov; T Masszi; A Hellmann; L Griskevicius; W Wiktor-Jedrzejczak; D Rea; D Coriu; T H Brümmendorf; K Porkka; G Saglio; G Gastl; M C Müller; P Schuld; P Di Matteo; A Pellegrino; L Dezzani; F-X Mahon; M Baccarani; F J Giles Journal: Leukemia Date: 2015-10-06 Impact factor: 11.528
Authors: Jorge E Cortes; Carlo Gambacorti-Passerini; Michael W Deininger; Michael J Mauro; Charles Chuah; Dong-Wook Kim; Irina Dyagil; Nataliia Glushko; Dragana Milojkovic; Philipp le Coutre; Valentin Garcia-Gutierrez; Laurence Reilly; Allison Jeynes-Ellis; Eric Leip; Nathalie Bardy-Bouxin; Andreas Hochhaus; Tim H Brümmendorf Journal: J Clin Oncol Date: 2017-11-01 Impact factor: 50.717
Authors: A Hochhaus; G Saglio; T P Hughes; R A Larson; D-W Kim; S Issaragrisil; P D le Coutre; G Etienne; P E Dorlhiac-Llacer; R E Clark; I W Flinn; H Nakamae; B Donohue; W Deng; D Dalal; H D Menssen; H M Kantarjian Journal: Leukemia Date: 2016-02-03 Impact factor: 11.528